Therefore, development of therapies based on dual and triple co-agonists of GLP-1, GIP and glucagon receptors might be of interest (Table 3), not only for T2D or obesity but also for NAFLD/NASH; however, more studies are needed. Here, GIP is linked to metabolic dysfunction-associated steatotic liver disease.